PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)

临床和实验治疗方案(方案4)是一个有凝聚力的综合方案 由7 523 204美元(年度直接费用)的同行审查资金支持，3 613 675美元由国家投资委员会提供。 委员会共有47名成员，分别代表9个部门。在总共747份成员同行评议的出版物中 在本赠款周期内，216个(29%)代表方案内活动，145(19%)代表方案内活动 程序间的协作。 该计划的总体目标是促进基础研究人员和临床研究人员之间的互动， 为癌症患者提供创新和有效的治疗方法。大部分作品的翻译性 从这个项目和许多项目教员在研究中承担的领导角色 由国家临床试验合作小组进行的研究说明了该计划在开发 肿瘤学的新疗法。该方案长期侧重于#年所有阶段的药物开发。 临床试验和很强的药物遗传成分。试验范围从临床前到临床前 发展到研究人员发起的第一阶段临床试验，到区域第二阶段网络中的第二阶段试验 到CALGB内的第三阶段研究。他们结合了相关的实验室研究，包括药代动力学 研究，基因分型研究，群体药理学，药物遗传学研究，以及 代理终结点。临床试验是由多学科团队进行的，这些团队由一组临床 代表医学肿瘤学、放射肿瘤学、病理学和适当外科的调查人员 特色菜。临床工作的重点是新药(细胞毒性或细胞抑制剂)的研究，临床和 翻译终点，当前化疗的调整，多学科治疗的排序， 器官保存、移植和强化治疗作为提高治愈率和 回应。成像、手术和病理支持被整合到该计划中。 科学目标是(1)促进基础和临床研究人员之间的互动，这将导致 创新有效的治疗方法；(2)将新药融入多模式发展 对晚期实体肿瘤患者的治疗；以及(3)追求广泛的临床前计划， 药物遗传学和药理学的翻译和临床研究。

The Clinical and Experimental Therapeutics Program (Program 4) is a cohesive, integrated program supported by $7,523,204 (annual direct costs) in peer-reviewed funding, with $3,613,675 from the NCI. There are 47 members representing nine departments. Of the total 747 member peer-reviewed publications during the current grant cycle, 216 (29%) represent intraprogrammatic, and 145 (19%) represent interprogrammatic collaborations. The overall goal of the Program is to foster interaction between basic and clinical investigators that will result in innovative and effective therapies for cancer patients. The translational nature of much of the work emanating from this program and the leadership role assumed by many program faculty in studies conducted by national clinical trials cooperative groups illustrates the impact of this program in developing new therapies for oncology. The Program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component. Trials span the gamut from preclinical development to investigator-initiated Phase I clinical trials, to Phase II trials in the regional Phase II network to Phase III studies within CALGB. They incorporate correlative laboratory studies including pharmacokinetic studies, genotyping studies, population pharmacology, pharmacogenetic studies, and the measurement of surrogate endpoints. Clinical trials are conducted by multidisciplinary teams comprised of a group of clinical investigators representing Medical Oncology, Radiation Oncology, Pathology, and appropriate surgical specialties. Clinical efforts focus on studies of new drugs (cytotoxic or cytostatic) with clinical and translational endpoints, modulation of current chemotherapy, sequencing of multidisciplinary treatment, organ preservation, transplantation, and treatment intensification as strategies to increase cure rates and response. Imaging, surgical, and pathology support are integrated into the Program. The scientific goals are (1) to foster interaction between basic and clinical investigators that will result in innovative and effective therapies; (2) to integrate new drugs into the development of multimodality therapies for patients with advanced solid tumors; and (3) to pursue a broad program of preclinical, translational, and clinical research in pharmacogenetics and pharmacology.